 Navidea Biopharmaceuticals, Inc. NYSE American: NAVB Navidea or the Company, a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce full enrollment in its ongoing NAV3-31 Phase 2B study titled Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value TUV on Tc99m Tilmanocept Planar Imaging. All of the subjects have been enrolled in the three-arm trial, and the study is on track for the last patient to be screened, and evaluated by end of 2020. The aim of this Phase 2B study is to evaluate the repeatability, reproducibility, and stability of Tc99m tilmanocept imaging in both healthy subjects Arm 1 and in patients with active RA Arm 2, as well as to assess the ability of Tc99m tilmanocept to provide an early indicator of efficacy of anti-tumor necrosis factor TNF alpha treatment in RA patients Arm 3. 